The new Kovid vaccine developed by leading pharmaceutical company Pfizer and BioNotech will begin to be available “at the end of this year or early next year” when all goes well. One of its producers gave this information on Sunday. Last week, Bioentech and its co-creator Pfizer said its vaccine analysis showed that it could be effective in protecting more than 90% of people against Kovid-19.
About 43,000 people participated in the survey. Bioentech co-founder and CEO Prof Ugur Sahin said by April next year the goal is to deliver more than 300 million doses worldwide.
He said: “The summer season will help us because the infection rate will decrease in the summer and it is very important that we achieve a higher vaccination rate before the fall / winter next year.”
He said: “If all goes well, the vaccine will start to be available at the end of this year or at the beginning of next year”.
Sahin said he was convinced the vaccine would reduce infection in people and at the same time prevent the development of symptoms in a person who received the vaccine. He said: “I am convinced that such effective vaccines should stop the spread of infection among people.”
He said this winter will be difficult again as the vaccine will not have a major impact on the number of infections. There have been 5,40,68,000 cases of this epidemic worldwide. The country most affected by the Corona virus is America. According to the latest figures from Johns Hopkins University, more than 1.09.08,000 cases of the outbreak have been reported in the United States and 2.45,600 people have died.
When asked if this vaccine was as effective in older people as it was in young people, he said he hoped to get better information in this regard in the next three weeks. The vaccine is one of 11 vaccines currently in the final stages of testing.
(This news item was not edited by the NDTV team. It is posted directly from the feed.)